Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma

Despite aggressive treatment with temozolomide and radiotherapy and extensive research into alternative therapies there has been little improvement in Glioblastoma patient survival. Median survival time remains between 12 and 15 months mainly due to treatment resistance and tumor recurrence. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Areeb, Zammam, Stuart, Sarah F., West, Alice J., Gomez, Juliana, Nguyen, Hong P. T., Paradiso, Lucia, Zulkifli, Ahmad, Jones, Jordan, Kaye, Andrew H., Morokoff, Andrew P., Luwor, Rodney B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576591/
https://www.ncbi.nlm.nih.gov/pubmed/33082482
http://dx.doi.org/10.1038/s41598-020-74746-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576591/
https://www.ncbi.nlm.nih.gov/pubmed/33082482
http://dx.doi.org/10.1038/s41598-020-74746-x

Ejemplares similares